NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

CompletedN/A

Sponsor: Pfizer

Conditions: SARS-CoV-2 Infection

Interventions: nirmatrelvir / ritonavir

Countries: Japan

The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be registered with the participants who: * Have taken PAXLOVID PACK and have no history of using this medicine. * Are 12 years and older All participants will receive PAXLOVID, a standard treatment for COVID-19. Participants will take PAXLOVID 2 times a day by mouth or as prescribed. We will examine the experiences of people taking PAXLOVID. This will help us determine if PAXLOVID is safe and effective. Participants will be followed up for 28 days after taking PAXLOVID. During this time, participants will be closely watched for the safety and effects of PAXLOVID.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Subjects who are administered PAXLOVID PACK and have no history of using this drug.

Exclusion Criteria:

* There are no exclusion criteria for this study.

Locations (1)

Tokyo, Japan